Increasing LRP4 diminishes neuromuscular deficits in a mouse model of Duchenne muscular dystrophy. Issue 17 (13th May 2021)

• Record Type: Journal Article
• Authors: Hui, Tiankun; Jing, Hongyang; Zhou, Tian; Chen, Peng; Liu, Ziyang; Dong, Xia; Yan, Min; Ren, Dongyan; Zou, Suqi; Wang, Shunqi; Fei, Erkang; Hong, Daojun; Lai, Xinsheng
• Is Part Of: Human molecular genetics. Volume 30:Issue 17(2021)
• Page Start: 1579
• Page End: 1590
• Publication Date: 2021-05-13
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddab135
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease characterized by progressive wasting of skeletal muscles. The neuromuscular junction (NMJ) is a synapse between motor neurons and skeletal muscle fibers, critical for the control of muscle contraction. The NMJ decline is observed in DMD patients, but the mechanism is unclear. LRP4 serves as a receptor for agrin, a proteoglycan secreted by motor neurons to induce NMJ, and plays a critical role in NMJ formation and maintenance. Interestingly, we found that protein levels of LRP4 were reduced both in muscles of the DMD patients and DMD model mdx mice. We explored whether increasing LRP4 is beneficial for DMD and crossed muscle-specific LRP4 transgenic mice with mdx mice (mdx; HSA-LRP4). The LRP4 transgene increased muscle strength, together with improved neuromuscular transmission in mdx mice. Furthermore, we found the LRP4 expression mitigated NMJ fragments and denervation in mdx mice. Mechanically, we showed that overexpression of LRP4 increased the activity of MuSK and expression of dystrophin-associated glycoprotein complex proteins in the mdx mice. Overall, our findings suggest that increasing LRP4 improves both function and structure of NMJ in the mdx mice and Agrin signaling might serve as a new therapeutic strategy in DMD.